Intra-Cellular Therapies Growth, Revenue, Number of Employees and Funding
Revenue & Financials
- Intra-Cellular Therapies's revenue is currently $9.2M per year.
- Intra-Cellular Therapies received $150.0M in venture funding in September 2017.
- Intra-Cellular Therapies's revenue per employee is $162211
- Intra-Cellular Therapies's total funding is $20.9M.
- Intra-Cellular Therapies has 57 Employees.
- Intra-Cellular Therapies grew their employee count by 24% last year.
- Intra-Cellular Therapies currently has 1 job openings.
What Is Intra-Cellular Therapies?
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications. Use link below for a listing of Job Opportunities: https://www.linkedin.com/jobs/search/keywords=intra-cellular%20therapies&location=United%20States&locationId=us%3A0keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|LI Script LLC||$10.9M||55||2%|
Intra-Cellular Therapies News
Intra-cellular Therapies Inc (NASDAQ:ITCI) institutional sentiment decreased to 0.93 in Q4 2018. Its down -0.01, from 0.94 in 2018Q3. The ratio
Intra-Cellular Therapies (ITCI) Q4 results: Revenues: $0; R&D Expense: $33.6M (+24.9%); SG&A: $9M (+55.2%); Net Loss: ($40.7M) (-34.8%);
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) popped in on a low volume green day. Volume on 12-Mar-19 came in at 246792 contracts.
Intra-Cellular Therapies Funding
|2014-02-03||$100.2M||Undisclosed||Leerink Partners LLC||Article|
|2014-02-06||$115.3M||Undisclosed||Leerink Partners LLC||Article|
|2015-03-09||$106.5M||Undisclosed||Leerink Partners LLC||Article|
|2015-03-13||$121.4M||Undisclosed||Leerink Partners LLC,||Article|
|2017-09-29||$150.0M||Undisclosed||J.P. Morgan Securities LLC||Article|
Intra-Cellular Therapies Executive Hires
|2014-03-11||Juan Sanchez||VP Corporate Communications/Investor Relations||Article|
|2018-08-21||Suresh Durgam||SVP Late Stage Clinical Development & Medical Affairs.||Article|
|2018-09-26||Michael Olchaskey||SVP/Head of Regulatory Affairs||Article|